- Home
- OPFI vs INZY Comparison
OPFI vs INZY Comparison
Compare OPFI & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- INZY
- Stock Information
- Founded
- OPFI 2009
- INZY 2015
- Country
- OPFI United States
- INZY United States
- Employees
- OPFI N/A
- INZY N/A
- Industry
- OPFI Finance: Consumer Services
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- INZY Health Care
- Exchange
- OPFI Nasdaq
- INZY Nasdaq
- Market Cap
- OPFI 174.4M
- INZY 188.2M
- IPO Year
- OPFI N/A
- INZY 2020
- Fundamental
- Price
- OPFI $12.76
- INZY $1.43
- Analyst Decision
- OPFI Buy
- INZY Strong Buy
- Analyst Count
- OPFI 2
- INZY 8
- Target Price
- OPFI $7.50
- INZY $17.75
- AVG Volume (30 Days)
- OPFI 1.9M
- INZY 854.7K
- Earning Date
- OPFI 03-06-2025
- INZY 03-11-2025
- Dividend Yield
- OPFI N/A
- INZY N/A
- EPS Growth
- OPFI 775.86
- INZY N/A
- EPS
- OPFI 0.38
- INZY N/A
- Revenue
- OPFI $260,661,000.00
- INZY N/A
- Revenue This Year
- OPFI N/A
- INZY N/A
- Revenue Next Year
- OPFI $6.51
- INZY N/A
- P/E Ratio
- OPFI $31.87
- INZY N/A
- Revenue Growth
- OPFI 23.85
- INZY N/A
- 52 Week Low
- OPFI $2.35
- INZY $1.24
- 52 Week High
- OPFI $12.50
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- OPFI 75.11
- INZY 23.52
- Support Level
- OPFI $11.45
- INZY $1.24
- Resistance Level
- OPFI $12.50
- INZY $1.44
- Average True Range (ATR)
- OPFI 1.03
- INZY 0.24
- MACD
- OPFI 0.31
- INZY -0.07
- Stochastic Oscillator
- OPFI 99.49
- INZY 7.46
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.